FC
REGN icon

Farringdon Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Farringdon Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,061
Closed -$597K – 612
2025
Q3 		$597K Buy
+1,061
New +$600K 0.15% 200
2025
Q2 		– Sell
-407
Closed -$258K – 568
2025
Q1 		$258K Buy
+407
New +$280K 0.13% 236

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Farringdon Capital's REGN Position: Q4 2025 in Review

Farringdon Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 1,061 shares — an estimated $597K sold.

Farringdon Capital first reported a position in REGN in Q1 2025 and held it in 2 quarters. The position peaked at $597K in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Farringdon Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Farringdon Capital sold 1,061 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $597K.
  • Farringdon Capital first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Farringdon Capital's Regeneron Pharmaceuticals position peaked at $597K in Q3 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Farringdon Capital's 13F filing for Q4 2025, filed 17 Feb 2026.